Lite Strategy, Inc. — Director's Dealing 2022

Jul 7, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: MEI Pharma, Inc. (MEIP)
CIK: 0001262104
Period of Report: 2022-07-05

Reporting Person: Reynolds Thomas C (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-07-05	Stock Option (Right to Buy)	$0.54	A	87500	Acquired	2032-07-05	Common Stock (87500)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$2.95	2031-07-01	Common Stock (50000)	50000	Direct
Stock Option (Right to Buy)	$1.57	2025-07-28	Common Stock (20000)	20000	Direct
Stock Option (Right to Buy)	$1.36	2026-07-29	Common Stock (40000)	40000	Direct
Stock Option (Right to Buy)	$2.83	2027-07-06	Common Stock (40000)	40000	Direct
Stock Option (Right to Buy)	$4.28	2028-07-12	Common Stock (40000)	40000	Direct
Stock Option (Right to Buy)	$2.52	2029-07-01	Common Stock (40000)	40000	Direct
Stock Option (Right to Buy)	$3.49	2030-07-02	Common Stock (50000)	50000	Direct

Footnotes

F1: The options will vest in equal monthly installments over twelve months.

F2: All of such options are presently exercisable.